1-3 of 3
Sanjay Koul
Close
Sort by
Journal Articles

Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells

Yongchao Wang, Warren Fiskus, Daniel G. Chong, Kathleen M. Buckley, Kavita Natarajan, Rekha Rao, Atul Joshi, Ramesh Balusu, Sanjay Koul, Jianguang Chen, Andrew Savoie, Celalettin Ustun, Anand P. Jillella, Peter Atadja, Ross L. Levine, Kapil N. Bhalla
Journal: Blood
Blood (2009) 114 (24): 5024–5033.
https://doi.org/10.1182/blood-2009-05-222133
Published: 2009
Includes: Supplemental data
Journal Articles

Targeting Levels, Aberrant Localization or Oligomerization of Mutant Nucleophosmin Induces Differentiation and Loss of Survival of Human AML Cells with Mutant NPM1.

Ramesh Balusu, Warren C. Fiskus, Rekha Rao, Kathleen M. Buckley, Yongchao Wang, Atul Joshi, Sanjay Koul, Anand Jillella, Celalettin Ustun, Susan Sunay, H. Jean Khoury, Kapil N. Bhalla
Journal: Blood
Blood (2009) 114 (22): 2656.
https://doi.org/10.1182/blood.V114.22.2656.2656
Published: 2009
Journal Articles

Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells

Warren Fiskus, Yongchao Wang, Arun Sreekumar, Kathleen M. Buckley, Huidong Shi, Anand Jillella, Celalettin Ustun, Rekha Rao, Pravina Fernandez, Jianguang Chen, Ramesh Balusu, Sanjay Koul, Peter Atadja, Victor E. Marquez, Kapil N. Bhalla
Journal: Blood
Blood (2009) 114 (13): 2733–2743.
https://doi.org/10.1182/blood-2009-03-213496
Published: 2009
Includes: Supplemental data